PD-L1 Reagents

ichorbio supplies a range of antibodies targeting PD-L1 including low endotoxin antibodies, biosimilar antibodies and conjugated antibodies. We also supply PD-L1 recombinant proteins and PD-L1 chemical inhibitors.

PD-L1 in vivo Antibodies

ichorbio supplies one low endotoxin antibody to PD-L1 – clone 10F.9G2 – product code ICH1086.

+
 Quick View

anti-mouse

Anti-Mouse PD-L1 In Vivo Antibody – Low Endotoxin (10F.9G2) [ICH1086]

$320.00 – $2,378.00

PD-L1 biosimilars

ichorbio supplies two antibodies which target PD-L1: Atezolizumab and Avelumab. Both antibodies are strictly for research use only; they are not medicinal grade and therefore are not for therapeutic purposes.

2020 FDA Approvals Atezolizumab
+
 Quick View

anti-human

Atezolizumab Biosimilar – Research Grade [ICH4018]

$704.00 – $4,080.00
2020 FDA Approvals Avelumab
+
 Quick View

anti-human

Avelumab Biosimilar – Research Grade [ICH4017]

$704.00 – $4,080.00

PD-L1 Conjugated antibodies

ichorbio supplies three conjugated antibodies to PD-L1

+
 Quick View

anti-mouse

Anti-Mouse PD-L1 Antibody (10F.9G2) – APC [ICH1086-APC]

$74.00 – $242.00
+
 Quick View

anti-mouse

Anti-Mouse PD-L1 Antibody (10F.9G2) – Biotin [ICH1086-B]

$79.00 – $279.00
+
 Quick View

anti-mouse

Anti-Mouse PD-L1 Antibody (10F.9G2) – PE [ICH1086-PE]

$58.00 – $174.00

Recombinant Proteins to PD-L1

ichorbio supplies human and mouse PD-L1 recombinant proteins.

+
 Quick View

Recombinant Proteins

Recombinant Human PD-L1 [ICH3060]

$519.00 – $3,537.00
+
 Quick View

Recombinant Proteins

Recombinant Mouse PD-L1 [ICH3058]

$490.00

PD-L1 Inhibitors

ichorbio supplies three inhibitors which target PD-1/PD-L1 interactions.

+
 Quick View

Inhibitors

PD-1/PD-L1 inhibitor (BMS202 hydrochloride) [ICH5003]

$71.00 – $707.00
+
 Quick View

Inhibitors

PD-1/PD-L1 inhibitor (BMS202) [ICH5004]

$71.00 – $1,210.00
+
 Quick View

Inhibitors

PD-1/PD-L1 inhibitor [ICH5002]

$88.00 – $618.00

Background to PD-L1

Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10).
The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy.
ichorbio supplies a range of products related to PD-1 including low endotoxin antibodies, biosimilar antibodies, conjugated antibodies and recombinant proteins.